JPMorgan Chase & Co. Lowers Repligen (NASDAQ:RGEN) Price Target to $165.00

Key Points

• JPMorgan cut its price target for Repligen from $180 to $165 but maintained an "overweight" rating, implying about a 31.2% upside from the current share price.
• Repligen beat Q1 estimates (EPS $0.48 vs. $0.38; revenue ~$194M, +14.8% y/y), reiterated FY‑2026 guidance (EPS $1.97–$2.05, revenue $803M–$833M) and is targeting a ~1 percentage‑point margin lift while expanding operations and China reach.
• Valuation is elevated (P/E ~148, PEG ~2.3) and the stock trades below its 200‑day moving average, a potential downside risk despite a consensus "Moderate Buy" and an average analyst target around $169.62.

Repligen (NASDAQ:RGEN - Get Free Report) had its target price decreased by research analysts at JPMorgan Chase & Co. from $180.00 to $165.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 31.20% from the stock's current price.

Several other equities research analysts have also commented on the company. Jefferies Financial Group restated a "hold" rating and issued a $142.00 price objective on shares of Repligen in a research report on Tuesday. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research report on Saturday, February 28th. Rothschild & Co Redburn set a $160.00 price objective on Repligen and gave the stock a "buy" rating in a research report on Friday, April 17th. Barclays upped their price objective on Repligen from $145.00 to $160.00 and gave the stock an "overweight" rating in a research report on Wednesday. Finally, KeyCorp restated an "overweight" rating on shares of Repligen in a research report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $169.62.

Repligen Stock Performance

NASDAQ:RGEN traded up $0.15 during midday trading on Wednesday, hitting $125.76. The company's stock had a trading volume of 1,625,385 shares, compared to its average volume of 889,344. Repligen has a fifty-two week low of $109.50 and a fifty-two week high of $175.77. The firm's 50 day moving average is $121.36 and its 200-day moving average is $144.51. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. The firm has a market cap of $7.09 billion, a P/E ratio of 147.95, a P/E/G ratio of 2.30 and a beta of 1.09.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company had revenue of $194.26 million for the quarter, compared to the consensus estimate of $192.05 million. During the same quarter in the prior year, the company earned $0.39 EPS. Repligen's quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities analysts anticipate that Repligen will post 1.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen during the 3rd quarter valued at approximately $29,000. Bayforest Capital Ltd purchased a new position in shares of Repligen during the 4th quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Repligen during the 4th quarter valued at approximately $33,000. Los Angeles Capital Management LLC purchased a new position in shares of Repligen during the 4th quarter valued at approximately $36,000. Finally, CWM LLC lifted its position in shares of Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company's stock valued at $45,000 after buying an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen News Roundup

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q1 beat on both EPS and revenue — Repligen posted $0.48 EPS vs. $0.38 expected and revenue of ~$194M (+14.8% y/y), which underpins the stock strength. Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
• Positive Sentiment: Company reiterated FY‑2026 EPS guidance at $1.97–$2.05 and is targeting a ~1 percentage‑point margin lift by end of 2027 — signals management expects operational improvement and margin expansion over the next 18 months. Repligen forecasts $1.97-$2.05 EPS on $803M-$833M 2026 revenue, as it targets 1 point margin lift
• Positive Sentiment: Management is reshaping operations and expanding its China reach — strategic moves management and analysts flag as potential upside drivers for revenue and valuation over time. Repligen Reshapes Operations And China Reach As Valuation Signals Upside
• Neutral Sentiment: Call and transcript available — management commentary (product demand, chromatography & analytics strength, and execution details) is accessible for investors doing deeper due diligence. Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: FY‑2026 revenue guidance set to $803M–$833M — provides a roadmap but the wide range makes near‑term visibility limited; midpoint is modestly below some sell‑side revenue estimates. Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
• Negative Sentiment: Valuation and multiples are elevated (P/E ~148, PEG ~2.3) and the 200‑day moving average sits above the current price — investors worried about stretched valuation or a slowdown could weigh on the stock. RGEN Stock Overview

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.